These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27873144)

  • 1. Truncation of the MSH2 C-terminal 60 amino acids disrupts effective DNA mismatch repair and is causative for Lynch syndrome.
    Wielders E; Delzenne-Goette E; Dekker R; van der Valk M; Te Riele H
    Fam Cancer; 2017 Apr; 16(2):221-229. PubMed ID: 27873144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional analysis of MSH2 unclassified variants found in suspected Lynch syndrome patients reveals pathogenicity due to attenuated mismatch repair.
    Wielders EA; Hettinger J; Dekker R; Kets CM; Ligtenberg MJ; Mensenkamp AR; van den Ouweland AM; Prins J; Wagner A; Dinjens WN; Dubbink HJ; van Hest LP; Menko F; Hogervorst F; Verhoef S; te Riele H
    J Med Genet; 2014 Apr; 51(4):245-53. PubMed ID: 24501230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants.
    Houlleberghs H; Dekker M; Lantermans H; Kleinendorst R; Dubbink HJ; Hofstra RM; Verhoef S; Te Riele H
    Proc Natl Acad Sci U S A; 2016 Apr; 113(15):4128-33. PubMed ID: 26951660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rapid and cell-free assay to test the activity of lynch syndrome-associated MSH2 and MSH6 missense variants.
    Drost M; Zonneveld JB; van Hees S; Rasmussen LJ; Hofstra RM; de Wind N
    Hum Mutat; 2012 Mar; 33(3):488-94. PubMed ID: 22102614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylation Tolerance-Based Functional Assay to Assess Variants of Unknown Significance in the MLH1 and MSH2 Genes and Identify Patients With Lynch Syndrome.
    Bouvet D; Bodo S; Munier A; Guillerm E; Bertrand R; Colas C; Duval A; Coulet F; Muleris M
    Gastroenterology; 2019 Aug; 157(2):421-431. PubMed ID: 30998989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
    Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
    Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elucidating the molecular basis of MSH2-deficient tumors by combined germline and somatic analysis.
    Vargas-Parra GM; González-Acosta M; Thompson BA; Gómez C; Fernández A; Dámaso E; Pons T; Morak M; Del Valle J; Iglesias S; Velasco À; Solanes A; Sanjuan X; Padilla N; de la Cruz X; Valencia A; Holinski-Feder E; Brunet J; Feliubadaló L; Lázaro C; Navarro M; Pineda M; Capellá G
    Int J Cancer; 2017 Oct; 141(7):1365-1380. PubMed ID: 28577310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional interrogation of Lynch syndrome-associated MSH2 missense variants via CRISPR-Cas9 gene editing in human embryonic stem cells.
    Rath A; Mishra A; Ferreira VD; Hu C; Omerza G; Kelly K; Hesse A; Reddi HV; Grady JP; Heinen CD
    Hum Mutat; 2019 Nov; 40(11):2044-2056. PubMed ID: 31237724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional analysis of HNPCC-related missense mutations in MSH2.
    Lützen A; de Wind N; Georgijevic D; Nielsen FC; Rasmussen LJ
    Mutat Res; 2008 Oct; 645(1-2):44-55. PubMed ID: 18822302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A putative Lynch syndrome family carrying MSH2 and MSH6 variants of uncertain significance-functional analysis reveals the pathogenic one.
    Kantelinen J; Hansen TV; Kansikas M; Krogh LN; Korhonen MK; Ollila S; Nyström M; Gerdes AM; Kariola R
    Fam Cancer; 2011 Sep; 10(3):515-20. PubMed ID: 21431882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional analysis in mouse embryonic stem cells reveals wild-type activity for three MSH6 variants found in suspected Lynch syndrome patients.
    Wielders EA; Houlleberghs H; Isik G; te Riele H
    PLoS One; 2013; 8(9):e74766. PubMed ID: 24040339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lynch syndrome-associated mutations in MSH2 alter DNA repair and checkpoint response functions in vivo.
    Mastrocola AS; Heinen CD
    Hum Mutat; 2010 Oct; 31(10):E1699-708. PubMed ID: 20672385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay.
    Bianchi F; Maccaroni E; Belvederesi L; Brugiati C; Giampieri R; Bini F; Bracci R; Pagliaretta S; Del Prete M; Piva F; Mandolesi A; Scarpelli M; Berardi R
    Fam Cancer; 2018 Apr; 17(2):215-224. PubMed ID: 28785832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic mechanisms in the pathogenesis of Lynch syndrome.
    Peltomäki P
    Clin Genet; 2014 May; 85(5):403-12. PubMed ID: 24443998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on Lynch syndrome genomics.
    Peltomäki P
    Fam Cancer; 2016 Jul; 15(3):385-93. PubMed ID: 26873718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Verification of the three-step model in assessing the pathogenicity of mismatch repair gene variants.
    Kansikas M; Kariola R; Nyström M
    Hum Mutat; 2011 Jan; 32(1):107-15. PubMed ID: 21120944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Massively parallel functional testing of MSH2 missense variants conferring Lynch syndrome risk.
    Jia X; Burugula BB; Chen V; Lemons RM; Jayakody S; Maksutova M; Kitzman JO
    Am J Hum Genet; 2021 Jan; 108(1):163-175. PubMed ID: 33357406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of pathogenicity in human MSH2 missense mutants.
    Ollila S; Dermadi Bebek D; Jiricny J; Nyström M
    Hum Mutat; 2008 Nov; 29(11):1355-63. PubMed ID: 18951462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome.
    Wojciechowicz K; Cantelli E; Van Gerwen B; Plug M; Van Der Wal A; Delzenne-Goette E; Song JY; De Vries S; Dekker M; Te Riele H
    Gastroenterology; 2014 Nov; 147(5):1064-72.e5. PubMed ID: 25088490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.